ArticlePediatric cardiology2010
The Fontan patient: inconsistencies in medication therapy across seven pediatric heart network centers.
Article in Pediatric cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 61 citations in OpenAlex.
- Cardiac performance and quality of life in patients who have undergone the Fontan procedure with and without prior superior cavopulmonary connection.Cardiology in the young · 2013Trial
- Changes in pharmacotherapy in adults with Fontan circulation and associations with outcomes.International journal of cardiology. Congenital heart disease · 2026Article
- Reduced Perfusion Pressure as a Predictor of Protein-Losing Enteropathy After Fontan Procedure: Beyond Central Venous Pressure.Pediatric cardiology · 2026Article
- Article
- Cardiac Medication Prescription Pattern and Association With Transplant-free Survival in the Adult Fontan Population.JACC. Advances · 2025Article
- Article
- Hypoplastic Left Heart Syndrome Practice Variation Across 31 Centres From 20 European Countries. An AEPC Imaging Working Group Study.European journal of pediatrics · 2025Article
- Lymphatic failure and lymphatic interventions: Knowledge gaps and future directions for a new frontier in congenital heart disease.Seminars in pediatric surgery · 2024Review
- Comparative Metabolomics in Single Ventricle Patients after Fontan Palliation: A Strong Case for a Targeted Metabolic Therapy.Metabolites · 2023Review
- Diuretic use in the adult Fontan.International journal of cardiology. Congenital heart disease · 2022Article
- Increased Risk for Thromboembolism After Fontan Surgery: Considerations for Thromboprophylaxis.Frontiers in pediatrics · 2022Article
- Prevalent pharmacotherapy of US Fontan survivors: A study utilizing data from the MarketScan Commercial and Medicaid claims databases.American heart journal · 2022Observational
- A Multimodal Score Accurately Classifies Fontan Failure and Late Mortality in Adult Fontan Patients.Frontiers in cardiovascular medicine · 2022Article
- Management of circulatory failure after Fontan surgery.Frontiers in pediatrics · 2022Review
- A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study.American heart journal · 2019Article
- Approaching the 50Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2017Review
- Longitudinal Outcomes of Patients With Single Ventricle After the Fontan Procedure.Journal of the American College of Cardiology · 2017Article
- Current Therapy for Hypoplastic Left Heart Syndrome and Related Single Ventricle Lesions.Circulation · 2016Review
- Clinical research priorities in adult congenital heart disease.International journal of cardiology · 2014Article
- Opportunities and challenges in linking information across databases in pediatric cardiovascular medicine.Progress in pediatric cardiology · 2012Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
Abstract
Patients who have undergone the Fontan procedure are at risk for thrombosis, ventricular dysfunction, and valve regurgitation, but data to guide the medical treatment and prevention of these adverse outcomes in this population are lacking. This analysis examined medication usage among Fontan patients by putative indication and by study center. The medical history and current medications of 546 Fontan subjects, ages 6-18 years, were assessed in a Pediatric Heart Network multicenter cross-sectional study. Cardiac imaging was performed within 3 months of enrollment. The majority of the subjects (64%) were taking two or more medications. Antithrombotics were taken by 86% of those with a history of stroke, thrombosis, or both and 67% of those without such a history (P = 0.01). Conversely, 14% of those with a history of stroke, thrombosis, or both were taking no antithrombotic. Angiotensin-converting enzyme inhibitor (ACEi) therapy was independently associated with moderate or severe atrioventricular valve regurgitation (P = 0.004), right ventricular morphology (P < 0.001), and shorter time since Fontan (P = 0.004) but not with ventricular systolic dysfunction. Glycoside therapy and diuretic therapy each was associated with older age at Fontan (P = 0.001 and P = 0.023, respectively) and a history of post-Fontan arrhythmia (P < 0.001 and P = 0.003, respectively) but not with ventricular systolic dysfunction. Medication use rates varied widely among the centers, even with controls for center differences in patient characteristics. Prospective therapeutic trials are needed to guide the medical treatment of Fontan patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.